Skip to main content
. 2019 Oct 13;6(4):102. doi: 10.3390/medicines6040102

Figure 2.

Figure 2

The siglec and sialoglycan axis in cancer. Siglec binding to hypersialylated tumour glycans blocks immune cell activation to promote immunosuppression.